side view of scientist looking into microscope in bright research lab

Lifesciences

China

As a participant in the lifesciences industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market. With over 150 international specialists across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
11/07/2016
Ex­pect­a­tion of a Faster Growth of Health Food in Near...
China In­sight - Lifes­ci­ences
05/04/2016
New GCP of Med­ic­al Devices
China In­sight - Lifes­ci­ences
05/04/2016
China En­cour­ages In­nov­at­ive Drug by Modi­fy­ing Its Drug...
China In­sight - Lifes­ci­ences

Feed

Show only
30/11/2016
China Lifes­ci­ences Monthly Up­date – Novem­ber 2016
CF­DA seeks pub­lic com­ments on the Ad­verse Events Mon­it­or­ing and Re-eval­u­ation of Med­ic­al Devices, 31 Oc­to­ber 2016 The Ad­min­is­trat­ive Meas­ures for the Ad­verse Events Mon­it­or­ing and Re-eval­u­ation of Med­ic­al Devices (Draft for Com­ment) (“Draft”) was pub­lished.